Condition
Low Grade Lymphoma
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (2)
P 2 (1)
Trial Status
Completed3
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04773769Not ApplicableUnknown
Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas
NCT01300026Phase 1Completed
AMG 319 Lymphoid Malignancy FIH
NCT00791011Phase 1Completed
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
NCT00144092Phase 2CompletedPrimary
HDCT and Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma
Showing all 4 trials